298 results about "Plasma sample" patented technology

The invention provides an immunodetection method of a multi-index immune checkpoint detection kit, which belongs to the technical field of immunodetection and comprises three main stages of sample preparation, immune reaction and data analysis. The method comprises the following steps: firstly, carrying out centrifugal separation to obtain a plasma sample, and preparing a fluorescent microsphere coupled capture antibody and biotin labeled detection antibody compound; then carrying out immune reaction, forming a sandwich type immune complex through specific binding, and adding streptavidin marked by phycoerythrin for signal amplification. Detecting a fluorescence signal by adopting a flow cytometer to obtain an original data matrix; a contribution feature vector, a utility feature vector and an expression feature matrix are extracted through a feature decomposition algorithm, and a deep learning model of a total-score-total structure is established for data analysis. Finally, a detection report containing a quantitative result, an importance score and reliability evaluation is generated, and the technical problem that in the prior art, the analysis accuracy of a multi-index immune checkpoint detection result is insufficient is solved.

The invention discloses an eRNA molecular marker for auxiliary diagnosis of colorectal cancer and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA eCOL4A1, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention further provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of colorectal cancer, and the eRNA molecular marker comprises a fluorescent quantitative PCR specific amplification primer for detecting the eRNA eCOL4A1 in a plasma sample, the nucleotide sequence of the upstream primer is 5 '-GGGCAGTGATGTGTAGATGAGTT-3', the nucleotide sequence of the downstream primer is 5 '-TGAACATCACATGGAGC-3', and the kit has the advantages that absolute quantitative detection of target molecules and early screening and identification of colorectal cancer can be rapidly and accurately completed only by a small amount of samples, and the kit is high in sensitivity, high in accuracy and rapid in detection.

A method for detecting the content of fluralana based on cat plasma relates to the technical field of detection of the content of fluralana, and comprises the following steps: extracting fluralana in a cat plasma sample by using an acetonitrile precipitation method, adding isotope deuterium-labeled fluralan-D4 as an internal standard, and quantifying the fluralana by using a UPLC-MS / MS method, verification parameters such as the quantitative range, the minimum quantitation limit, the intra-day and inter-day accuracy and precision of the analyte fluralana in the cat plasma and the selectivity and the recovery rate of the method all meet the requirements; after ULOQ is measured every time, an acetonitrile sample is continuously injected, the analyte residual quantity meets the requirement, the established method for measuring the flurala in the plasma through LC / MS / MS meets the requirement of the related guiding principle, the method is applied to the pharmacokinetics method of the flurala drops in the cat body, and the content of the flurala in the cat plasma sample can be accurately quantified.

Disclosed herein includes a method of detecting RhD incompatibility during pregnancy, comprising: a) extracting DNA from a blood sample of a pregnant mother; b) performing qPCR on the DNA to determine Ct values of at least one RhD exon and at least one internal control gene; and c) calculating a ΔCt value between the at least one RhD exon and at least one internal control gene.

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

The invention discloses a colorectal cancer plasma circulating microbial marker, a reagent, a kit and application thereof, and belongs to the technical field of biomedical detection. The plasma circulating microbial marker for colorectal cancer comprises alternaria alternata, alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous The colorectal cancer plasma circulating microbial marker can be used for early screening of colorectal cancer, has relatively high sensitivity and specificity, and remarkably improves the accuracy and reliability of detection; the limitation of traditional ctDNA detection is broken through, and the detection rate of early colorectal cancer is improved. The colorectal cancer plasma circulating microbial marker in a colorectal cancer plasma sample is detected through low-depth whole genome sequencing, the requirement for depth in an experiment is reduced, the cost can be greatly reduced while high sensitivity and specificity are guaranteed, and the method is more suitable for large-scale screening.

The invention discloses a method for annotating a vesicle cell subset based on monovesicle membrane proteomics, and belongs to the technical field of vesicle cell annotation. The method comprises the following steps: 1, carrying out exosome collection on a plasma sample to obtain a sample; 2, coding and labeling the antibody probe, and adding a protein tag and a labeled DNA sequence into the antibody probe to obtain a labeled antibody probe; 3, preparing a corresponding combined product; 4, adding a labeled antibody probe into the sample to obtain an exosome compound; step 5, capturing an exosome conjugate through CTB; 6, adding the binding product into the exosome conjugate to generate a sequence; 7, constructing a sequence library and sequencing to obtain a sequencing sequence; 8, removing a sequencing sequence with low expression quantity to obtain an exosome expression data matrix, and standardizing the exosome expression data matrix; 9, carrying out clustering analysis to find out an exosome core subgroup; and step 10, determining the source of the exosome core subgroup, and annotating the single vesicle subgroup.

A method of pre-screening a human subject for a clinical trial for treatment of tauopathy or an amyloidogenic disease. The method comprises obtaining a plasma sample from the subject and determining a concentration of p217+tau present in the plasma sample. The method further comprises indicating the subject for further screening for the clinical trial when the concentration of p217+tau present in the plasma sample is greater than or equal to a minimum threshold and less than or equal to a maximum threshold. The minimum threshold corresponds to an amount of p217+tau in plasma over which subjects present with mild cognitive impairment (MCI) and an increased accumulation of tau tangles in the brain as compared to a cognitively normal patient. The maximum threshold corresponds to an amount of p217+tau present in plasma over which subjects present with pathology of widespread accumulation of tau tangles in multiple regions of the brain.

The invention relates to the field of biological medicine, and discloses application of LPC, PC and AA in children sepsis diagnosis and prognosis product development. According to the invention, a high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) technology is used, plasma samples of a child sepsis patient and a healthy control group are compared, the relationship between lipidome change and pSOFA score is analyzed, and specific lipid molecules closely related to disease severity and prognosis are identified. According to the invention, the following lipid molecules are highlighted as key biomarkers: lysophosphatidylcholine (LPC), phosphatidylcholine (PC) and arachidonic acid (AA). The change of the lipid molecules is closely related to the physiological state of a child sepsis patient, and the lipid molecules can be used for early diagnosis and evaluation of the state of the child sepsis, so that the treatment effect and the accuracy of prognosis evaluation are improved, and a new treatment strategy and a new management method are provided for clinic.

A device for detecting and / or quantifying functional C1-esterase inhibitor (fC1-INH), the device comprising: (i) a conjugate pad comprising a first zone and a second zone, on which a first agent and a second agent are immobilized, respectively, and (ii) a membrane, which is in communication with the conjugate pad, wherein the membrane comprises a third zone, on which a third agent is immobilized. The conjugate pad may further comprise a fourth zone for placing a biological sample, which flows through the device in the order of the first zone, the second zone, and the third zone.

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

Nucleic acid error suppression is provided. In various embodiments, DNA is extracted from a collection of plasma samples. A sequence library with duplex adapters is prepared by ligating a duplex adapter having a Unique Molecule Identifier (UMI) to an end of each of a plurality of strands of the extracted DNA and amplifying the extracted DNA with a first polymerase chain reaction (PCR). A subset of the whole genome library is selected and amplified with a second PCR to increase an amount of PCR duplicates. A plurality of duplex reads is sequenced from the amplified subset aligned to a host genome and denoised based on said alignment. A variant presence is detected in at least one of the plurality of duplex reads. A signature of the variant is determined, which is compared to a collection of disease-specific variant signatures. A disease type is determined based on the comparison.

The invention discloses a brain-derived Tau protein single-molecule fluorescence immunoassay detection kit and a use method, the kit provided by the invention is composed of a BD-Tau magnetic bead reagent coated with a capture antibody, a BD-Tau calibrator, a BD-Tau quality control product, a biotinylated BD-Tau Detector reagent for detecting the antibody, a BD-Tau SBG reagent, an RGP reagent and a BD-Tau sample diluent, the magnetic bead concentration of the BD-Tau magnetic bead reagent is 0.04 mg / mL-0. 08mg / mL of carboxyl magnetic beads, the carboxyl magnetic beads are coated with Tau J5.H3 coated antibodies, the detection antibody in the BD-Tau Detector reagent of the biotinylated detection antibody is Tau12, the concentration of the detection antibody is 0.3 mu g / mL-0. 8mu g / mL, and the concentration of SBG in the BD-Tau SBG reagent is 40 pM-60 pM; the kit disclosed by the invention can be used by adopting any one of a one-step method, a two-step method or a three-step method to detect the content of the BD-Tau protein in a plasma sample, the detection limit is 0.050 pg / mL, and the detection range is 0.050 pg / mL-150 pg / mL; according to the invention, the specificity, accuracy and reliability of determination of the Alzheimer's disease are improved, and the problems of early diagnosis and early screening of the Alzheimer's disease are solved.

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.

The invention relates to the technical field of biological detection, in particular to a sample diluent as well as a preparation method and application thereof. The sample diluent comprises a dilution component, and the dilution component comprises the following raw materials in percentage by mass: 0.005%-0.02% of thermally denatured immunoglobulin G, 0.5%-2.0% of a protein protective agent, 0.5%-1.5% of a metal ion chelating agent, 0.1%-0.5% of an ampholytic surfactant and 0.5%-2.0% of a sugar alcohol compound. According to the sample diluent, through the interaction of all the components, the ability of the sample diluent to reduce the matrix effect of serum and plasma samples can be remarkably improved, so that the interference of non-specific reaction and matrix effect of serum and plasma on the detection process is reduced, and the accuracy of serum and plasma sample detection can be improved; and a more reliable and accurate experiment result can be obtained.

The invention discloses a data processing method, device, system and equipment, a medium and a program product, and is applied to the technical field of data processing. The method comprises: acquiring a plasma sample of a user; the plasma sample is detected, expression data of biomarkers are obtained, the biomarkers comprise markers related to carotid plaque occurrence, and the expression data of the biomarkers comprise the expression quantity of the biomarkers in the plasma sample; and based on the expression data of the biomarker, determining a risk score value of the user, the risk score value being used for representing a risk probability of occurrence of the carotid plaque of the user within a preset time period. According to the method, the risk probability of carotid plaque occurrence of the user within the preset time can be judged.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

本发明实施例公开了一种基于蛋白质组学的脓毒症休克患者液体管理策略预测方法。所述方法包括：收集脓毒症休克患者的血浆样本，检测蛋白质标志物的表达水平，所述蛋白质标志物为GAL、NFASC、MICB_MICA、MAP2K6、JCHAIN和CSF3的组合；基于亚组识别模型计算效益得分，获得脓毒症休克患者的液体管理策略结果。本发明通过收集脓毒症休克患者的临床数据和蛋白质表达数据，采用LASSO回归分析，构建基于上述蛋白质标志物的亚组识别模型，进而获得效益评分，基于效益评分能预测患者液体管理策略方案的适用性，为脓毒症休克患者的液体治疗提供了可靠的方案，实现个体化和精准的液体治疗，在临床具有较好的应用前景。

The application discloses a method for determining unbound concentration of lenvatinib, which comprises the following steps: sending standard curve working solution and quality control working solution into a liquid chromatography tandem mass spectrometry detection system to obtain a standard curve; adding a plasma sample into an ultrafiltration tube, centrifuging under the condition of a centrifugal force of 3000g for 15 min, and collecting an ultrafiltrate of the plasma sample; adding the ultrafiltrate of the plasma sample into blank plasma ultrafiltrate, mixing uniformly, taking supernatant into a collection plate, sending the collection plate into the liquid chromatography tandem mass spectrometry detection system to obtain a ratio of a peak area of lenvatinib to a peak area of an internal standard, and then bringing the area ratio into the standard curve to obtain the unbound concentration of lenvatinib in the plasma sample. The method for determining the unbound concentration of lenvatinib can accurately determine the unbound concentration of lenvatinib in plasma and overcome the prejudice of the prior art.

Systems, methods and computer-readable media are provided for identifying patients having an elevated near-term risk of chronic kidney disease (CKD) progression, including predicting an individual's risk of progression to Stage 3 CKD within a future time interval, which may be up to 36 months. Based on the prediction, appropriate care providers may be notified so that the risk of CKD progression may be mitigated. In an embodiment, measurements of physiological variables are obtained, including serial measurements for uric acid levels from a longitudinal time series of serum or plasma samples spanning the previous two to five years. An annualized uric acid velocity of the patient is determined and used to generate a multivariable mathematical model for determining a likelihood of risk for developing Stage 3 CKD within 36 months.

A system for determining a functional fibrinogen concentration from a patient's coagulating blood or blood plasma sample is configured to obtain a signal representing physical or biochemical properties of the developing fibrin network during coagulation of the patient's blood or blood plasma sample over time, determine the fibrinogen concentration based on one or more values of one or more features of the signal with the help of a learned function which maps values of the feature(s) to functional fibrinogen concentrations, and output the fibrinogen concentration, e.g. on a display. The feature(s) include(s) multiple of features related to 1) a maximum value of the gradient of the signal, 2) the maximum of the second derivative of the signal, 3) a difference between the maximum and the minimum of the signal, and 4) the minimum of the second derivative of the signal, or at least feature 1) or 2).

The present invention provides the use of a reagent for detecting a target compound combination in the preparation of a detection agent, and the detection agent is used for screening and identifying whether a subject under test has taken drugs for treating vertigo, syncope or stroke, and assisting in determining whether the subject suffers from related diseases. Among them, the target compound combination includes one, several or all of lidocaine, cinepazide maleate, ticlopidine, penbutolol, fendiline, cinnarizine, clopidogrel, midodrine, dipyridamole, argatroban, rosuvastatin, atorvastatin, fluvastatin, and pitavastatin. The plasma sample pretreatment method of the present invention is simple, the detection and analysis time is short, the sensitivity of the method is high, and the types and quantities of detections are many; the method is divided into a primary screening method and a review method, which can improve the accuracy of the detection results and avoid false negative and false positive results.

Despite the high prevalence and serious clinical implications of metabolic associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), MASH is usually overlooked in clinical practice, due to the lack of accurate biomarkers. The inventors evaluated the ability of plasma large extracellular vesicles (lEVs) to serve as noninvasive biomarkers for the diagnosis of MASH, in particular in T2D patients. Proteomic analysis identified Transferrinreceptor on lEVs (TFRC-lEVs) as associated with MASH. The inventors thus measured TFRC- lEVs on plasma samples from patients included in the derivation cohort. The proportion of patients with TFRC-lEVs concentration > 61 ng / mL was significantly higher in patients with MASH than in those with steatosis. TFRC-lEVs > 61 ng / mL remained associated with MASH after adjustment on either usual laboratory variables, or on the NASH-Test or on the Fibroscan FAST-score. When combining TFRC-lEVs with available methods the population suspected of having MASH was 32% and 29%, versus 22% and 16% for NASH-test or FAST score alone, without decreasing specificity. In conclusion, TFRC-lEVs, a marker of hepatocyte ballooning, is a promising biomarker for MASH. It could be used for patients' screening to enlarge recruitment of patients with MASH in clinical trials.

Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.

This invention relates to a method for detecting tRF-type gastric cancer molecular markers in plasma and their application in the preparation of a gastric cancer auxiliary diagnostic kit. The kit is characterized by including reagents for detecting tRF-18-79MP9P04, tRF-30-87R8WP9N1EWJ, tRF-21-V2989UV3B, and tRF-33-P4R8YP9LON4VDP in plasma samples. Compared with existing technologies, the advantages of this invention are: the kit combines tRF-18-79MP9P04, tRF-30-87R8WP9N1EWJ, tRF-21-V2989UV3B, and tRF-33-P4R8YP9LON4VDP as markers for the auxiliary diagnosis of early gastric cancer, enabling accurate absolute quantitative detection of target molecules and screening and identification of early gastric cancer.

The invention relates to oil seal liquid and application thereof in blood coagulation detection, and belongs to the technical field of blood coagulation detection. The oil seal liquid can form a uniform film when covering a plasma sample, the activity of thrombin is not affected while air is isolated, and in addition, the oil seal liquid is a biological inert formula, is easy to clean and does not generate adsorption or reaction with blood coagulation factors and reagents. Therefore, the oil seal liquid and the sample are incubated synchronously in the pre-warming stage, and errors caused by sample evaporation and temperature fluctuation in the pre-warming stage can be reduced. Compared with traditional paraffin oil, the oil seal liquid can effectively isolate air to avoid sample evaporation and reduce reagent interference, is easy to clean, provides reliable technical support for blood coagulation factor deficiency and precise identification of inhibitors, and is suitable for APTT correction experiments, PT correction experiments or clinical detection and application of lupus anticoagulant (LA).

Ovarian cancer risk in a female human subject is predicted by determining the amount of STK1 substance in a serum or plasma sample from the female human subject using first and second monoclonal antibodies or antigen-binding fragments thereof that specifically bind to the serum form of human TK1. The amount of CA 125 or HE4 is determined in the serum or plasma sample or another serum or plasma sample from the female human subject. The risk of ovarian cancer in the female human subject is then predicted based on the amount of STK1 substance and the amount of one but not both of CA 125 and HE4.

The invention relates to a method for detecting the concentration content of maropitant based on canine plasma, which comprises the following steps: S1, preparing canine blank plasma, selecting 2-4-year-old beagle, collecting blood in a non-anesthetic state, filling the blood into a heparin sodium anticoagulation blood collection tube, centrifuging for 10 minutes at 4 DEG C and 4000 rpm, separating the plasma, and cryopreserving at low temperature; s2, preparing an internal standard working solution, a double-blank sample, a matrix effect reference pure solution sample, a matrix effect sample and a recovery rate sample, and preparing an analyte standard substance (glasspirenn) and an internal standard substance (trazodone); the invention relates to the technical field of detection of the content of glasspiren. According to the method, a trazodone internal standard method is adopted for determination, and the established content determination method for analyzing and determining the analyte glasspirenn in the dog plasma by using the ultra-high performance liquid chromatography-tandem mass spectrometer is good in accuracy and high in precision, and can be applied to plasma sample content determination in pharmacokinetic research of the analyte glasspirenn in a dog body.

The application discloses a CKD and IgAN early detection method based on blood mass spectrum analysis, utilizes liquid chromatography-tandem mass spectrometry technology to detect 24 kinds of compounds of a plasma sample in a targeted manner, utilizes a logic regression to establish an early detection model of CKD and IgAN, and verifies the prediction accuracy of CKD and IgAN in a cohort. Through analysis of plasma samples of healthy controls and CKD patients (including IgAN and non-IgAN patients), it is proved that the melatonin or melatonin+tryptophan level in the plasma is an effective method for detecting early CKD, and the melatonin, tryptophan, indole-3-lactic acid, indole-3-carboxylic acid, kynurenic acid and indole-3-methyl aldehyde are effective methods for detecting early IgAN. The application provides effective blood markers for early detection of CKD and IgAN.